$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
一分钟带你了解利妥昔单抗的作用功效及注意事项
2025-10-19 11:44:20
Check Details
利妥昔单抗的治疗效果如何?常见的不良反应有哪些
2025-10-19 11:44:20
Check Details
百时美施贵宝的Breyanzi和吉利德的Yescarta在早期淋巴瘤治疗中势均力敌
2025-10-19 11:44:20
Check Details
Yescarta®一线治疗高危大B细胞淋巴瘤,完全缓解率可达78%!
2025-10-19 11:44:20
Check Details
Yescarta®对非霍奇金淋巴瘤成人患者显示出两年的持久临床疗效
2025-10-19 11:44:20
Check Details
Kymriah®治疗复发或难治性滤泡性淋巴瘤高风险患者疗效强大
2025-10-19 11:44:20
Check Details
第一三共公司授权日本第一家YESCARTA® CAR-T细胞治疗中心
2025-10-19 11:44:20
Check Details
Pirtobrutinib在1/2期临床试验中显示出持久的疾病控制
2025-10-19 11:44:20
Check Details
Parsaclisib治疗数据更新:复发或难治性B细胞非霍奇金淋巴瘤患者可产生快速且持久的缓解
2025-10-19 11:44:20
Check Details
在南京可以买到杜韦利西布吗?多少钱?
2025-10-19 11:44:20
Check Details
YTB323治疗复发/难治性DLBCL显示出良好的有效性和安全性
2025-10-19 11:44:20
Check Details
2021年套细胞淋巴瘤治疗取得了哪些进展?
2025-10-19 11:44:20
Check Details
1
2
...
1268
1269
1270
1271
1272
1273
1274
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
2
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
3
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
4
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
5
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
6
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
7
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
8
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
9
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
10
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
11
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
12
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile